» Articles » PMID: 1498578

Preliminary Examination of the Comorbidity of Anxiety and Depression in Parkinson's Disease

Overview
Specialties Neurology
Psychiatry
Date 1992 Jan 1
PMID 1498578
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Significant anxiety in combination with depression may represent a specific depressive subtype in Parkinson's disease (PD). To ascertain the prevalence of this symptom complex, we administered a self-report survey and standardized psychological tests that measure anxiety and depression to 164 PD patients and 150 age-matched healthy spouse control subjects. The reporting of depression in combination with panic/anxiety best differentiated the two populations (38% vs. 8%). Depression and anxiety were highly correlated in relationship to clinical features of PD. Our findings suggest that clinically significant levels of depression and anxiety may frequently coexist in PD. The specific neuropathology of PD may predispose to this pattern of behavioral disturbance.

Citing Articles

Predictors of anxiety in Parkinson's disease: results from a 3-year longitudinal cohort study.

Gibson J, Flanigan J, Patrie J, Dalrymple W, Harrison M Neurol Sci. 2022; 44(2):547-556.

PMID: 36216970 PMC: 9842547. DOI: 10.1007/s10072-022-06427-8.


Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Antipova V, Holzmann C, Hawlitschka A, Witt M, Wree A Toxins (Basel). 2021; 13(7).

PMID: 34357977 PMC: 8310221. DOI: 10.3390/toxins13070505.


An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB).

Lang F, Kwon D, Aarsland D, Boeve B, Tousi B, Harnett M Alzheimers Dement (N Y). 2021; 7(1):e12171.

PMID: 34189249 PMC: 8215076. DOI: 10.1002/trc2.12171.


A Stage-Based Approach to Therapy in Parkinson's Disease.

Carrarini C, Russo M, Dono F, Di Pietro M, Rispoli M, Di Stefano V Biomolecules. 2019; 9(8).

PMID: 31434341 PMC: 6723065. DOI: 10.3390/biom9080388.


Evaluating the Link Between Dopaminergic Treatment, Gait Impairment, and Anxiety in Parkinson's Disease.

Ehgoetz Martens K, Ellard C, Almeida Q Mov Disord Clin Pract. 2018; 3(4):389-394.

PMID: 30363509 PMC: 6178607. DOI: 10.1002/mdc3.12298.